# AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer

Source: https://onco.cc/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/  
OnCo record `paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding bevacizumab to single-agent chemotherapy for platinum-resistant ovarian cancer doubled the time to progression and more than doubled the response rate, without a significant gain in survival.

## Summary

Open-label randomised phase 3 trial: 361 women with platinum-resistant recurrent ovarian cancer received the investigator's choice of weekly paclitaxel, pegylated liposomal doxorubicin or topotecan, alone or with bevacizumab.

Median progression-free survival was 6.7 months with bevacizumab against 3.4 months (hazard ratio 0.48, p < 0.001); response rate 27.3 against 11.8 percent; median overall survival 16.6 against 13.3 months (hazard ratio 0.85, p 0.174). Grade 2 or higher hypertension and proteinuria were more common with bevacizumab; gastrointestinal perforation occurred in 2.2 percent.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Journal: Journal of Clinical Oncology
- Year: 2014
- DOI: 10.1200/JCO.2013.51.4489
- Authors: Pujade-Lauraine E, Hilpert F, Weber B, et al.
- Findings: Median progression-free survival 6.7 versus 3.4 months; hazard ratio 0.48 (95% CI 0.38 to 0.60), p < 0.001.; Objective response 27.3 versus 11.8 percent (p 0.001).; Median overall survival 16.6 versus 13.3 months; hazard ratio 0.85 (0.66 to 1.08), not significant.
- What it means: Bevacizumab with weekly paclitaxel, liposomal doxorubicin or topotecan is a standard option in platinum-resistant ovarian cancer; approved in the United States in 2014.
- Caveats: Open-label; patients with more than two prior regimens or bowel involvement at risk of perforation were excluded.; Crossover to bevacizumab at progression diluted the survival comparison.

## Sources

- J Clin Oncol 2014: https://doi.org/10.1200/JCO.2013.51.4489
- PubMed: https://pubmed.ncbi.nlm.nih.gov/24637997/

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- trials: [AURELIA](https://onco.cc/trials/aurelia/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014.json